To evaluate the effectiveness of latanoprost and dorsolamide/timolol fixed combination therapy as initial treatment for glaucoma patients with high intraocular pressure

Abstract

Objectives: To evaluate the effectiveness of latanoprost and dorsolamide-timolol fixed combination therapy as initial treatment for treatment naïve patients with intraocular pressure (IOP) values over 30 mm Hg. Methods: Twenty-five eyes of 25 newly diagnosed patients whose IOP measurements were at least 30 mmHg and who did not receive any antiglaucomatous medication previously were included in the study. Sixteen eyes had primary open angle glaucoma and 9 eyes had pseudoexfoliation glaucoma. Visual acuity, iridocorneal angle, intraocular pressure, optic nerve head and computerized visual field test were evaluated in each patient. Patients were evaluated on the first and third months of therapy for IOP reduction and ocular side effects. Results: The baseline average IOP was 38.4 ± 7.0 mmHg initially, at first month average IOP was 16.3± 3.7mmHg and at third month average IOP was 18.6 ± 4.2 mmHg. IOP reduction from baseline was 22.1 ± 9.0 mmHg (55.7± 14.5 %) for the first month, 19.8 ± 8.9 mmHg (49.6 ± 15.9 %) for the third month (p=0.0001) None of the patients reported any serious side-effects about therapy. Five (20%) had moderate hyperemia, 2 (8%) reported metallic taste. Conclusion: The combined therapy of latanoprost and dorsolamide/timolol fixed combination as initial treatment for intraocular pressure over 30 mmHg is highly efficient and well tolerated for treatment naive glaucoma. J Clin Exp Invest 2014; 5 (4): 443-446

Keywords

• Dorsolamide, latanoprost, timolol, pseudoexfoliation glaucoma, primary open angle glaucoma

Göz içi basıncı yüksek glokom hastalarında başlangıç tedavisi olarak latanoprost ve dorzolamid/timolol fiks kombinasyon etkinliğinin değerlendirilmesi

Öz

Amaç: Önceden tedavi görmemiş olan yüksek basınçlı glokom olgularında başlangıç tedavisinde latanoprost ve dorzolamid/timolol sabit kombinasyonunun etkinliğinin değerlendirilmesi Yöntemler: Çalışmaya yeni tanı almış ve daha önce glokom tedavisi uygulanmamış, göz içi basıncı ölçümü 30 mmHg ve üzerinde olan 25 hasta dahil edildi. On altı gözde primer açık açılı glokom, 9 gözde psödoeksfoliasyon glokomu mevcuttu. Görme keskinliği, göz içi basıncı (GİB), bilgisayarlı görme alanı ölçümleri, iridokorneal açı ve optik sinir başını içeren oftalmolojik muayeneleri yapıldı. Hastalar tedavinin 1. ve 3.ayında GİB düşüşü ve yan etki profili açısından değerlendirildi. Bulgular: Başlangıç GİB değeri ortalama 38,4 ± 7 mmHg, 1. ay GİB değeri ortalama 16,3 ± 3,7 mmHg ve 3. ay GİB değeri ortalama 18,6 ± 4,2 mmHg olarak saptandı. Başlangıç GİB değerine göre 1. ayda 22,1 ± 9 mmHg (%55,7 ± 14,5), üçüncü ayda 19,8 ± 8,9 mmHg (%49,6 ± 15,9) düşüş sağlandı (p=0,0001). Hastaların hiçbirinde ciddi yan etki görülmedi. Beş (%20) hastada hafif hiperemi gözlenirken, iki (%8) hastada ağızda metalik tat şikayeti ile karşılaşıldı. Sonuç: Göz içi basıncı 30 mmHg\'nın üzerindeki hastalarda başlangıç tedavisi olarak latanoprost ve dorzolamid/timolol sabit kombinasyonun erken dönemde oldukça etkili olduğunu ve yan etki profili açısından tolere edilebilir olduğunu söyleyebiliriz.

Anahtar Kelimeler

• Dorzolamid, latanoprost, timolol, psödoeksfoliasyon glokomu, primer açık açılı glokom

References

1. Rosenberg LF, Krupin T. Primary Open Angle Glauco- ma. In: Yanoff M, Duker SJ, eds. Ophthalmology. 1st ed. St. Louis: Mosby,1999.
2. O’Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002;133:836-837.
3. Fechtner RD, Airaksinen PJ, Getson AJ, et al. Cosopt versus Xalatan Study Groups Efficacy and tolerabi- lity of the dorzolamide 2%/timolol 0.5% combination (Cosopt) versus 0.005% (Xalatan) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004;82:42-48.
4. Camras CB, Alm A, Watson P, et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Effi- cacy and safety after 1 year of treatment in 198 pa- tients. Latanoprost Study Groups. Ophthalmology 1996;103:1916-1924.
5. García Sanchez J. Efficacy and side effects of latano- prost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hy- pertension-a three-month randomised study. Span- ish Latanoprost Study Group. Eur J Ophthalmol 2000;10:198-204.
6. Konstas AG, Kozobolis VP, Tersis I, et al. The effica- cy and safety of the timolol/dorzolamide fixed com- bination vs latanoprost in exfoliation glaucoma. Eye (Lond) 2003;17:41-46.
7. Bron AM, Emmerich KH. Latanoprost versus com- bined timolol and dorzolamide. Surv Ophthalmol 2002;47:148-154.
8. Emmerich KH. Comparison of latanoprost monother- apy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study. Graefes Arch Clin Exp Ophthalmol 2000;238:19-23.

9. Simmons ST, Earl ML. Three month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients un- controlled on beta blockers. Ophthalmology 2002; 109:307-315.
10. Pajic B. Conductors of the Swiss Cosopt Survey (CSCS).Experience with Cosopt, the fixed combi- nation of timolol and dorzolamide, gained in Swiss ophthalmologists’ offices. Curr Med Res Opin 2003; 19:95-101.
11. Henderer JD, Wilson RP, Moster MR, et al. Timolol/ dorzolamide combination therapy as initial treatment for intraocular pressure over 30 mm Hg. J Glaucoma 2005; 14:267-270.
12. Sakarya R, Gozoglu S, Sur N et al. Efficacy and safe- ty of long-term monotherapy of timolol + dorzolamide (cosopt) in the treatment of glaucoma. Turk J Ophthal- mol 2005; 35: 401-405.
13. Yaycıoglu AR, Turker G, Izgi B, et al. The Effects of latanoprost 0.005% and timolol maleate 0.50% on daily intraocular pressure. Turk J Ophthalmol 2000; 30: 725-729.
14. Uzun I, Cetinkaya K. Comparison of the effects of antiglaucomatous fixed combinations and patients compliance: Dorzolamide-timolol maleate and latano- prost-timolol maleate. Dicle Med J 2012;39:61-69.
15. Susanna R Jr, Nicolela MT, Oga E. Additive effect of latanoprost to the combination of timolol and dorzol- amide. J Glaucoma 2000; 9:183-186.